Indian CAR-T vs Imported: Kymriah, Yescarta and Carvykti

The published gap is roughly tenfold. India’s two approved CAR-T products were announced at about US$50,000 and US$60,000 per dose. Kymriah’s United States list price has been reported at US$475,000, and Yescarta’s at US$373,000. Every figure here is a product price only, indicative as of August 2026 — not a treatment estimate.

The comparison is worth making carefully, because the two sides of it are not the same kind of number. The Indian figures are launch prices announced by the manufacturer for the Indian market. The American figures are list prices in a system that almost never pays list. Both are still useful, because the order of magnitude between them is not in dispute.

One line in that table matters more than the prices. Carvykti targets BCMA, and both Indian products target CD19. They are not alternatives to one another. A family reading about myeloma CAR-T abroad is reading about a treatment with no Indian equivalent to compare on price, not a cheaper version of the same thing.

All prices above are manufacturer announcements or figures reported in published sources, named and dated, and are indicative only as of August 2026. They are product prices, not the cost of a course of care, and CION does not price, quote or supply any of these products. What a hospital charges is a matter for that hospital’s written estimate.

No trial has compared them head to head. Each product was tested in its own single-arm study, in different patients, diseases, countries and years. The reported response rates sit in a broadly similar range. Reading numbers from separate trials as a ranking overstates what those trials were designed to show.

That is the honest position, and it is neither a dismissal of the Indian products nor a sales pitch for them. It is what the study designs allow anyone to say. Here is what each approval actually rests on.

Two further points belong here, and they cut in opposite directions. On safety, the reported Indian registration experience was encouraging: among the 53 evaluable participants, severe cytokine release syndrome was reported in about 5%, no neurological events were reported, and only five participants needed hospitalisation for side effects. Those numbers come from the December 2023 conference presentation, summarised by the United States National Cancer Institute in February 2024.

On maturity, the Indian products are young. NexCAR19 has been authorised since October 2023 and Qartemi since January 2025, so the long-term record that has accumulated abroad over nearly a decade does not yet exist here. Anyone who tells you the long-term outcomes are settled either way is going beyond the published evidence. Real-world follow-up from Indian centres is being collected now, and that is how the gap gets closed.

Clinical statements on this page follow published Indian regulatory information (CDSCO), the trial data presented and reported for each product, and general patient-education material from bodies such as NCCN, ASCO and ESMO. No survival figure is given for any product on this page, and no product is presented as better than another.

Not in practice. None of Kymriah, Yescarta or Carvykti is routinely supplied at Indian hospitals, and no CDSCO marketing authorisation for them could be confirmed when this page was reviewed in August 2026. Treat that status as unconfirmed rather than settled, and check it with the treating centre.

The more important point is that CAR-T is not an imported vial, so the usual thinking about arranging a medicine from abroad does not transfer. There is no stock of Kymriah sitting in a warehouse waiting for a buyer. Each dose is manufactured for one named patient from that patient’s own cells.

The sequence is fixed. The patient’s T cells are collected by apheresis at a licensed centre. They are frozen and shipped to the manufacturing site. They are genetically modified, grown, tested and released. Then they are shipped back, thawed and infused into the same patient, under an unbroken chain of identity and custody that has to be documented at every step. A relative abroad cannot buy that and bring it back, at any price, and no intermediary offering to arrange it privately should be taken at face value.

What this means for an Indian family is that the practical choice is between the products approved and made here, at the centres licensed to give them, and no treatment with CAR-T at all. Where is CAR-T therapy available in India? lists how to identify those centres and what a referral to one involves.

CAR-T is not an option for the great majority of people with cancer in India, and the price comparison on this page is meaningless until eligibility has been settled first. Both Indian products are CD19-directed, which limits them to specific B-cell lymphomas and B-cell acute lymphoblastic leukaemia that have relapsed after, or not responded to, standard treatment. Solid tumours — breast, lung, head and neck, colorectal, cervical and the rest — are not treated with either approved Indian CAR-T product. Multiple myeloma is treated with BCMA-directed products, which are a different class and have no approved Indian equivalent as of August 2026.

Even within the eligible diagnoses, a haematologist assesses much more than the diagnosis itself. Organ function, performance status, control of the disease while the cells are being manufactured, active infection, central nervous system involvement, prior treatment lines and the ability to stay near a licensed centre for weeks all bear on whether CAR-T is safe and sensible for one person. Cytokine release syndrome and neurological toxicity can require intensive care at short notice, which is why the treatment is confined to centres equipped for it.

This page is also not a recommendation to use any named product, a quality ranking between manufacturers, or an offer to supply anything. CION Cancer Clinics does not provide, administer, stock or arrange CAR-T or cell therapy. Whether CAR-T applies to a particular patient, and which product and centre would be appropriate, is a decision for a treating haematologist or medical oncologist at a licensed cell therapy centre.

Because of where and how it is made, not because a lower standard was applied. Both Indian products hold CDSCO marketing authorisation granted on Indian trial data. Manufacturing at home removes cross-border shipping of living cells in both directions, local costs are lower, and both were priced for the Indian market rather than converted from a dollar list price.

NexCAR19 was designed at IIT Bombay and developed with Tata Memorial Centre in Mumbai, with early training support from the United States National Cancer Institute, and it is manufactured in India. Qartemi reached Immuneel Therapeutics through a licence from Hospital Clínic de Barcelona, where the earlier work was done, and was taken through an Indian phase 2 trial. In both cases a large share of the development cost sat with academic and public institutions rather than being recovered entirely through the price of the product.

The logistics matter as much as the science. Shipping frozen cells out of India, manufacturing abroad and shipping them back would add cost, time and risk to every single dose, because there is no batch to share it across. Domestic manufacture removes that entirely, and it shortens the wait between collection and infusion, which is not a small thing for a patient whose disease is active.

What a lower price does not mean is a lower regulatory bar. CDSCO treats CAR-T as a new drug, and both Indian products went through Indian clinical trials before authorisation. The same logic applies here as with Indian-made versus imported immunotherapy more broadly: the country on the carton is not the quality signal people assume it is.

Most of the hospital care around it. The announced price is for the product. Cell collection, bridging treatment, lymphodepleting chemotherapy, the admission for infusion, intensive care if cytokine release syndrome develops, supportive drugs, monitoring and weeks of staying near the centre are billed separately. Ask for one itemised written estimate covering all of it.

This is why two families quoted the same product price can end up with very different totals, and why a number heard from another family is a poor guide to your own. The variable is not the product. It is how the admission goes. A course with no complications and one that needs a week in intensive care are not the same episode of care.

Funding routes are worth understanding before the estimate arrives rather than after. Insurance and scheme coverage for CAR-T by product sets out what policies and government schemes have actually paid for, and getting CAR-T at a government hospital covers subsidised pathways and the waiting lists attached to them.

Every figure on this page is indicative, as of August 2026, and drawn from published manufacturer announcements or reporting. Prices change, and only the treating centre can give a written estimate for one patient.

Six questions cover the ground. Am I eligible at all. Which product and why. What the itemised estimate covers. What happens if the disease progresses during manufacturing. How long we must stay near the centre. And what the alternatives are, including the option of continuing with standard treatment instead.

1. Am I eligible for CAR-T at all? This comes before every cost question. Diagnosis, treatment line, organ function and disease control all decide it, and the answer is often no.
2. Which product would be used, and why that one? Both Indian products are CD19-directed, but their approved indications differ, and the centre’s own experience with a product is a legitimate part of the answer.
3. What does the written estimate include? Ask for the product, the admission, intensive care provision, supportive drugs and follow-up as separate lines, not one bundled figure.
4. What happens if the disease progresses while the cells are being made? Manufacturing takes weeks. Ask what the bridging plan is, and what happens to the money already committed if the infusion cannot go ahead.
5. How long must we stay near the centre? Families routinely underestimate this. It shapes both the true cost and whether the plan is workable for your household.
6. What are the alternatives? Ask what standard treatment would look like instead, and what the trade-offs are. A comparison against the alternative is the only comparison that helps you decide.

None of these questions is unusual, and none requires a confrontation. A cell therapy centre that has thought its programme through will have all six answers ready.

The pages below deal with the practical side of CAR-T in India — where it is given, who pays, and how the subsidised routes work.

• Where Is CAR-T Therapy Available in India? — how to identify a licensed cell therapy centre and what a referral to one involves.
• Getting CAR-T at a Government Hospital: Subsidies and Waiting Lists — the subsidised pathway, and the realistic waiting times attached to it.
• Insurance and Scheme Coverage for CAR-T by Product — what policies and government schemes have actually paid for so far.
• Immunotherapy Medicines Explained — the index of checkpoint inhibitors, biosimilars, cell therapies and molecule comparisons.
• Immunotherapy at a glance — what this family of treatments does, who it is for, and who it is not for.

Editorial and referral orientation about CAR-T products available in India and abroad — not an offer, a price list, a quality ranking between named manufacturers, or a recommendation to use any named product. CION Cancer Clinics does not provide, administer, stock or arrange CAR-T or any other cell therapy. All approval, availability and pricing statements are indicative and dated to August 2026, drawn from published regulatory information, manufacturer announcements and reporting. Whether CAR-T applies to your treatment, and at which centre, is a decision for your treating haematologist or medical oncologist.